Kyverna Therapeutics is a technology company.
Kyverna Therapeutics has raised $170.0M across 3 funding rounds.
Kyverna Therapeutics has raised $170.0M in total across 3 funding rounds.
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing chimeric antigen receptor (CAR) T-cell therapies to treat autoimmune diseases.[1][2][3] It builds advanced cell therapies that engineer patients' T cells to target and deplete autoreactive B cells, aiming for an immune system reset and long-term, treatment-free remission.[2][4] Kyverna serves patients with serious autoimmune conditions like lupus and myasthenia gravis, where current therapies often fail or cause long-term toxicities such as infections or malignancies.[1][2] The company addresses the vast unmet need for curative alternatives by leveraging oncology-proven CAR T technology for autoimmune applications, with ongoing global clinical trials and partnerships like ElevateBio for manufacturing.[2][4]
Kyverna, based in the San Francisco East Bay, emerged from the insight that cell engineering advances for cancer could transform autoimmune disease treatment, where many conditions lack effective options.[3] Founded by leaders with expertise in synthetic biology, immunology, cell engineering, and drug development, the company harnessed interdisciplinary talent to pioneer CAR T-cell therapies for autoimmunity.[1][3][4] Early pivotal moments include applying deep B cell depletion strategies from hematological malignancies to autoimmune diseases, leading to active clinical programs and collaborations like the 2023 ElevateBio partnership for scalable Ingenui-T manufacturing.[2][4] This patient-centric approach has driven rapid progress toward potentially curative therapies.[1][5]
Kyverna rides the wave of CAR T-cell therapy expansion from oncology to autoimmune diseases, capitalizing on proven B cell-targeting success in cancers like lymphoma to address a market of over 50 million U.S. patients with inadequate treatments.[2][3] Timing is ideal amid rising autoimmune prevalence, regulatory momentum for cell therapies (e.g., FDA approvals in oncology paving non-oncology paths), and biotech investment in curative modalities.[4][6] Favorable forces include advances in cell engineering for off-the-shelf allogeneic products and manufacturing scalability, reducing costs and access barriers.[4] Kyverna influences the ecosystem by validating autoimmune CAR T, inspiring pipeline diversification, and partnering with investors like Bain Capital to accelerate biotech innovation globally.[6]
Kyverna is poised for milestone readouts from ongoing trials in lupus and other indications, potentially unlocking blockbuster status if remission data holds, with allogeneic therapies enabling broader scalability.[2][4] Trends like AI-optimized cell engineering, combo regimens with immunomodulators, and global trial expansion will shape its path, amid a biotech funding rebound favoring high-impact platforms.[6] Its influence could evolve from pioneer to category leader, redefining autoimmune care as curative rather than chronic—echoing its mission to liberate patients through cell therapy's transformative potential.[1][2]
Kyverna Therapeutics has raised $170.0M in total across 3 funding rounds.
Kyverna Therapeutics's investors include Access Biotechnology, Northpond Ventures, venBio, Westlake Village BioPartners, Sean Harper.
Kyverna Therapeutics has raised $170.0M across 3 funding rounds. Most recently, it raised $60.0M Series B in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2023 | $60.0M Series B | Access Biotechnology, Northpond Ventures, venBio, Westlake Village BioPartners, Sean Harper | |
| Jan 1, 2022 | $85.0M Series B | Access Biotechnology, Northpond Ventures, venBio, Westlake Village BioPartners, Sean Harper | |
| Jan 1, 2020 | $25.0M Series A | Access Biotechnology, venBio, Westlake Village BioPartners, Sean Harper |